drugset / Trial / NCT02966249

Dexmetomidine Intrathecally and Intravenously Additionally to Spinal Anaesthesia, in Total Knee Arthroplasty

NCT02966249

Phase 4 Unknown 90 enrolled KAT General Hospital
RandomizedFactorialDouble-blindTreatment

Summary

The present study is designed to evaluate and compare the efficacy of intrathecal dexmedetomidine (DEX) as an adjuvant to Levobupivacaine in spinal anaesthesia and DEX's intravenous administration, without loading dose, additionally to spinal anaesthesia, in patients undergoing total knee arthroplasty.

Timeline

Start
2016-10
Primary completion
2017-04
Completion
2017-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmetomidine Unknown 0.25 ug/kg Intrathecal
Subject Dexmetomidine Unknown 5 ug Intrathecal
Background Levobupivacaine Other / unclassified 15 mg Intrathecal

Indications